AAAAAA

   
Results: 1-11 |
Results: 11
PHASE-III STUDY COMPARING METHOTREXATE AND TACROLIMUS (PROGRAF, FK506) WITH METHOTREXATE AND CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION
Authors: RATANATHARATHORN V NASH RA PRZEPIORKA D DEVINE SM KLEIN JL WEISDORF D FAY JW NADEMANEE A ANTIN JH CHRISTIANSEN NP VANDERJAGT R HERZIG RH LITZOW MR WOLFF SN LONGO WL PETERSEN FB KARANES C AVALOS B STORB R BUELL DN MAHER RM FITZSIMMONS WE WINGARD JR
Citation: V. Ratanatharathorn et al., PHASE-III STUDY COMPARING METHOTREXATE AND TACROLIMUS (PROGRAF, FK506) WITH METHOTREXATE AND CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION, Blood, 92(7), 1998, pp. 2303-2314
ARE THERAPEUTIC DECISIONS SUPPORTED BY EVIDENCE FROM HEALTH-CARE RESEARCH
Authors: MICHAUD G MCGOWAN JL VANDERJAGT R WELLS G TUGWELL P
Citation: G. Michaud et al., ARE THERAPEUTIC DECISIONS SUPPORTED BY EVIDENCE FROM HEALTH-CARE RESEARCH, Archives of internal medicine, 158(15), 1998, pp. 1665-1668
RESPONSE-ADAPTED THERAPY OF DE-NOVO ACUTE MYELOBLASTIC-LEUKEMIA (AML)- UPDATE OF A PHASE-II MULTICENTER STUDY OF SEQUENTIAL INDUCTION REGIMENS IDALUBICIN CYTARABINE AND MITOXANTRONE/ETOPOSIDE/
Authors: VANDERJAGT R ROBINSON S GLUCK S BELCH A SHERIDAN D MATTHEWS J LARRATT L MARKMAN S DIPIETRO N PHAM B SHUSTIK C STEWART K
Citation: R. Vanderjagt et al., RESPONSE-ADAPTED THERAPY OF DE-NOVO ACUTE MYELOBLASTIC-LEUKEMIA (AML)- UPDATE OF A PHASE-II MULTICENTER STUDY OF SEQUENTIAL INDUCTION REGIMENS IDALUBICIN CYTARABINE AND MITOXANTRONE/ETOPOSIDE/, Blood, 90(10), 1997, pp. 2264-2264
ONCE-DAILY CEFTRIAXONE FOR FEBRILE NEUTROPENIA IN AN OUTPATIENT BLOODAND MARROW TRANSPLANT PROGRAM
Authors: KHALIQ Y BENCEBRUCKLER I BREDESON C VANDERJAGT R MCDIRAMID S HUEBSCH LB
Citation: Y. Khaliq et al., ONCE-DAILY CEFTRIAXONE FOR FEBRILE NEUTROPENIA IN AN OUTPATIENT BLOODAND MARROW TRANSPLANT PROGRAM, Blood, 86(10), 1995, pp. 837-837
RESPONSE-ADAPTED TREATMENT OF DE-NOVO ACUTE MYELOBLASTIC-LEUKEMIA (AML) - A PHASE-II MULTICENTER STUDY OF SEQUENTIAL INDUCTION REGIMES IDARUBICIN CYTARABINE AND MITOXANTRONE/ETOPOSIDE/
Authors: VANDERJAGT R ROBINSON S GLUCK S BELCH A SHERIDAN D MATTHEWS J LARRATT L MARKMAN S DIPIETRO N PHAM B SHUSTIK C STEWART K
Citation: R. Vanderjagt et al., RESPONSE-ADAPTED TREATMENT OF DE-NOVO ACUTE MYELOBLASTIC-LEUKEMIA (AML) - A PHASE-II MULTICENTER STUDY OF SEQUENTIAL INDUCTION REGIMES IDARUBICIN CYTARABINE AND MITOXANTRONE/ETOPOSIDE/, Blood, 86(10), 1995, pp. 2051-2051
TACROLIMUS (FK506) ALONE OR IN COMBINATION WITH METHOTREXATE OR METHYLPREDNISOLONE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MARROW TRANSPLANTATION FROM HLA-MATCHED SIBLINGS - A SINGLE-CENTERSTUDY
Authors: NASH RA ETZIONI R STORB R FURLONG T GOOLEY T ANASETTI C APPELBAUM FR DONEY K MARTIN P SLATTERY J SULLIVAN K VANDERJAGT R WITHERSPOON R JUSKO WJ ZAGER RA DEEG HJ
Citation: Ra. Nash et al., TACROLIMUS (FK506) ALONE OR IN COMBINATION WITH METHOTREXATE OR METHYLPREDNISOLONE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MARROW TRANSPLANTATION FROM HLA-MATCHED SIBLINGS - A SINGLE-CENTERSTUDY, Blood, 85(12), 1995, pp. 3746-3753
REARRANGEMENT OF THE BCR ABL AND TCR-BETA GENES IN LYMPH-NODE BLAST CRISIS DIAGNOSED OF CHRONIC MYELOID-LEUKEMIA - REPLY/
Authors: VANDERJAGT R DROUIN J GIULIVI A HUEBSCH LB TITTLEY P
Citation: R. Vanderjagt et al., REARRANGEMENT OF THE BCR ABL AND TCR-BETA GENES IN LYMPH-NODE BLAST CRISIS DIAGNOSED OF CHRONIC MYELOID-LEUKEMIA - REPLY/, American journal of hematology, 46(3), 1994, pp. 248-248
HIGH-DOSE CHEMORADIOTHERAPY WITH UNPURGED MARROW (BM) AND OR BLOOD STEM-CELL (BC) SUPPORT FOR FOLLICULAR NON-HODGKINS-LYMPHOMA
Authors: HUEBSCH L LEGER C BREDESON C BURNELL M BUTTS C GENEST P GIULIVI A MARKMAN S MCDIARMID S VANDERJAGT R
Citation: L. Huebsch et al., HIGH-DOSE CHEMORADIOTHERAPY WITH UNPURGED MARROW (BM) AND OR BLOOD STEM-CELL (BC) SUPPORT FOR FOLLICULAR NON-HODGKINS-LYMPHOMA, Blood, 84(10), 1994, pp. 10000208-10000208
A PHASE-II MULTICENTER STUDY OF SEQUENTIAL, RESPONSE-ADAPTED INDUCTION REGIMENS IDARUBICIN CYTARABINE AND MITOXANTRONE ETOPOSIDE, FOR TREATMENT OF DE-NOVO AML
Authors: VANDERJAGT R ROBINSON S GLUCK S SHERIDAN D MATHEWS J BELCH A LARRATT L MARKMAN S SHUSTIK C HO AD
Citation: R. Vanderjagt et al., A PHASE-II MULTICENTER STUDY OF SEQUENTIAL, RESPONSE-ADAPTED INDUCTION REGIMENS IDARUBICIN CYTARABINE AND MITOXANTRONE ETOPOSIDE, FOR TREATMENT OF DE-NOVO AML, Blood, 84(10), 1994, pp. 10000304-10000304
COMPREHENSIVE COST-ANALYSIS OF INNOVATION IN HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION
Authors: BREDESON C MALCOLM J DAVIS M GIULIVI A MCDIARMID S VANDERJAGT R GENEST P HUEBSCH L
Citation: C. Bredeson et al., COMPREHENSIVE COST-ANALYSIS OF INNOVATION IN HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION, Blood, 84(10), 1994, pp. 10000493-10000493
FK-506 AND METHOTREXATE PREVENT GRAFT-VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 GY TOTAL-BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN-NONIDENTICAL DONORS
Authors: STORB R RAFF RF APPELBAUM FR DEEG HJ FITZSIMMONS W GRAHAM TC PEPE M PETTINGER M SALE G VANDERJAGT R SCHUENING FG
Citation: R. Storb et al., FK-506 AND METHOTREXATE PREVENT GRAFT-VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 GY TOTAL-BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN-NONIDENTICAL DONORS, Transplantation, 56(4), 1993, pp. 800-807
Risultati: 1-11 |